BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 53,700 shares, an increase of 67.3% from the January 15th total of 32,100 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average trading volume of 49,700 shares, the short-interest ratio is currently 1.1 days.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BCDA shares. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of BioCardia in a research report on Wednesday, December 18th. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th.

Institutional Investors Weigh In On BioCardia

An institutional investor recently raised its position in BioCardia stock. Geode Capital Management LLC increased its holdings in BioCardia, Inc. (NASDAQ:BCDA) by 110.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,987 shares of the company’s stock after acquiring an additional 16,251 shares during the quarter. Geode Capital Management LLC owned about 0.68% of BioCardia worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Stock Performance

BCDA traded up $0.06 on Thursday, hitting $2.69. 22,520 shares of the company were exchanged, compared to its average volume of 48,520. The stock has a market capitalization of $12.33 million, a PE ratio of -0.64 and a beta of 1.30. BioCardia has a 12 month low of $1.63 and a 12 month high of $8.85. The firm has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $2.49.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.